| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000412933 |
| ISSN: | 1665-2681 |
| Autores: | Ching-Chung Lin1 Chia-Hsien Wu1 Huan-Lin Chen1 I-Tsung Lin1 Shen-Yung Wang1 I-Tsung Lin1 Shen-Yung Wang1 Tsang-En Wang1 Horng-Yuan Wang1 Shou-Chuan Shih1 Ming-Jong Bair1 |
| Instituciones: | 1Mackay Memorial Hospital, Department of Internal Medicine, Taipei. Taiwán |
| Año: | 2014 |
| Periodo: | Jul-Ago |
| Volumen: | 13 |
| Número: | 4 |
| Paginación: | 350-355 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, caso clínico |
| Resumen en inglés | The treatment efficacy of peginterferon plus ribavirin for patients with HCV genotype 1 is inferior to that in patients with HCV genotype 2, but the efficacy among patients with mixed HCV genotype 1 + 2 is less clear. We compared the treatment outcome of peginterferon alpha-2b plus ribavirin among naïve chronic hepatitis C patients in Taiwan with HCV genotype 1 and 2, and mixed genotype 1 + 2. Material and methods. In this retrospective cohort study, 150 patients were treated with peginterferon alpha-2b once weekly, plus ribavirin, for 24 weeks. The endpoint was sustained virological response after receiving at least one dose of the study medication. Results. There were no differences in clinical characteristics among the 3 groups. There were significant differences in rapid virological response rate between patients with genotype 1 and genotype 2 (64.7 vs. 85.5%, respectively; p < 0.05) and a sustained virological response rate (55.9 vs. 83.6%, respectively; p = 0.001). The rapid virological response rate differed between the genotype 1 and mixed genotype 1 + 2 groups (64.7 vs. 85.2%, respectively; p < 0.05), but the sustained virological response rate was similar (55.9 vs. 74.1%; p = 0.101). Conclusions. Using peginterferon alpha-2b plus ribavirin for 24 weeks to treat patients with HCV genotype 1 + 2 achieved a 74.1% sustained virological response rate; the treatment efficacy was not inferior to patients with HCV genotype 1, but the percentage of liver cirrhosis in mixed genotype 1 + 2 group was higher to 22%, it is worth to be appropriately valued and studied |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Terapéutica y rehabilitación, Virus, Hepatitis C, Genotipos, Interferón, Ribavirina, Infecciones mixtas, Eficacia |
| Keyword: | Medicine, Gastroenterology, Therapeutics and rehabilitation, Virus, Hepatitis C, Genotypes, Interferon, Ribavirin, Mixed infections, Efficacy |
| Texto completo: | Texto completo (Ver PDF) |
